Focused On-demand Library for Matrin-3

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
P43243

UPID:
MATR3_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P43243; B7ZAV5; D3DQC3; Q9UHW0; Q9UQ27

BACKGROUND:
The protein Matrin-3 plays a critical role in transcription regulation, RNA stability, and the innate immune response. It forms part of the HDP-RNP complex, facilitating IRF3 phosphorylation essential for activating the cGAS-STING pathway in response to DNA virus infection. Matrin-3's ability to bind to m6A-modified mRNAs and specific miRNA hairpins further highlights its regulatory capacity in gene expression and stability, particularly concerning the MYC oncogene.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Amyotrophic lateral sclerosis 21, a condition leading to significant motor neuron degeneration, Matrin-3 presents a promising target for developing novel therapeutic approaches. Exploring Matrin-3's functions and interactions could pave the way for breakthrough treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 790 of 8789